Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21941031 | 0.88 | MEN1 (0.34) | MEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL21541171 | 0.85 | MEN1 (0.33) | MEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL20104610 | 0.85 | MEN1 (0.36) | MEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL24529722 | 0.79 | MEN1 (0.36) | MEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL20104600 | 0.77 | MEN1 (0.35) | MEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL16260138 | 0.73 | MEN1 (0.39) | MEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL21559872 | 0.73 | MEN1 (0.34) | MEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL13254058 | 0.72 | ITGB3 (0.34) | MEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL23489658 | 0.72 | ITGB3 (0.34) | MEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL22413623 | 0.70 | KISS1R (0.39) | MEN1CYP1A2KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10640544-B2 | Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors | JANSSEN PHARMACEUTICA NV (BE) | 2020-05-05 | — | — | US | disclosed |
| US-20180117170-A1 | ANTIBODY-COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10640544-B2 | Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors | NPY1R, NPY5R, NPY2R | MEN1 1303/4885CYP1A2 4749/4885KMT2A 2481/4885 |
| US-20180117170-A1 | ANTIBODY-COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | NPY1R, NPY5R, NPY2R | MEN1 1303/4885CYP1A2 4749/4885KMT2A 2481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.